None listed
Conditions
Interventions
Procedure/Surgery : Standard group: Ramosetron 0.3 mg is intravenously administered once at the end of surgery. As a placebo, normal saline (1 ml) is intravenously administered daily until 2 days afte
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Female 2. Patients 20 to 70 years old 3. Body weight ? 45 kg 4. American Society of Anesthesiologist Physical Status 1, 2 or 3 5. Apfel simplified PONV risk score ? 3 (3 or more of the 4 items below) • Female • History of PONV and/or motion sickness • Nonsmoking status • Use of postoperative opioids 6. Patients undergoing elective breast surgery (breast-conserving surgery or mastectomy) 7 Patients who signed a written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test 2. Patients with known hypersensitivity to ramosetron 3. Patients with known hypersensitivity to oxycodone 4. Clinically significant impairment of renal function, defined by estimated GFR < 60 ml/min or a need for hemodialysis 5. Family history of malignant hyperthermia 6. Patients who are considered by the investigator to be unsuitable to participate in the study for any other reason not mentioned in the inclusion and exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of nausea, vomiting, or retching for 48 hours after the end of surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| - Severity of PONV assessed by Rhodes index for nausea, vomiting and retching at 6, 24, and 48 hours after the end of surgery (0-32) - Frequency and amount of rescue antiemetics usage for 48 hours after the end of surgery | — |
Countries
Korea, Republic of
Contacts
Public ContactByung-Moon Choi
Asan Medical Center
Outcome results
None listed